Boston Scientific completes purchase of Bayer AG unit
Boston Scientific has completed its purchase of the interventional business of Bayer AG, opening up the Marlborough-based company’s treatment solutions for vascular conditions.
"We look forward to welcoming the Bayer Interventional team to Boston Scientific (BSX), and we are confident that the addition of its innovative technologies will help us bring unique value to healthcare systems worldwide," said Jeff Mirviss, president of peripheral interventions for BSX. "Physicians who perform endovascular procedures encounter a variety of challenging conditions and require a broad-range of tools to treat these difficult disease states.”
In May, BSX announced it would buy the Minneapolis-based unit for an estimated $415 million in cash.
The purchase includes the AngioJet Thrombectomy System and the Fetch 2 Aspiration Catheter, which are used in endovascular procedures to remove blood clots from arteries and veins. Also included in the sale is the JetStream Atherectomy System, used in a therapy to remove plaque and thrombi from diseased arteries.
“The inclusion of the leading thrombectomy device and a differentiated atherectomy technology adds meaningful breadth to our product portfolio and will allow us to help physicians save the lives and limbs of more patients worldwide," said Mirviss.
BSX’s peripheral interventions division develops and commercializes products to treat the estimated 27 million people worldwide who suffer from peripheral vascular disease.
WBJ Web Partners
Most Recent
Most Recent
0 Comments